BriaCell Therapeutics Corp. (BCTX) Other Non-Current Liabilities (2021 - 2026)

BriaCell Therapeutics has reported Other Non-Current Liabilities for 6 years, with the latest figure at $71854.0 in Q2 2026.

• Quarterly Other Non-Current Liabilities fell 90.16% year-over-year to $71854.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $71854.0 (down 90.16% YoY) and the FY2025 annual result came in at $337672.0, down 69.19% from the prior year.
• Other Non-Current Liabilities declined to $71854.0 in Q2 2026 per BCTX's latest filing, from $195096.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $34.8 million in Q1 2023 and troughed at $71854.0 in Q2 2026.
• A 5-year average of $11.1 million and a median of $1.4 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 96.86% in 2022, then surged 13893.32% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $27.1 million in 2022, then slumped by 44.53% to $15.1 million in 2023, then slumped by 88.62% to $1.7 million in 2024, then sank by 76.24% to $406873.0 in 2025, then plunged by 82.34% to $71854.0 in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $71854.0, $195096.0, and $406873.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.